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SUMMARY 
Arginine is added to commercially available recombinant tissue plasminogen 
activator (rtPA) to promote its solubility. However, arginine is also known to inhibit 
certain proteases. To explore the possibility that arginine inhibits the highly 
concentrated rtP A in commercial formulations, we tested the amino acid in assays 
of tP A function. Although arginine was found to inhibit rtP A cleavage of a 
chromogenic substrate, it did not interfere with rtP A-mediated fibrinolysis. Nor did 
it inhibit plasmin activity. However, the coagulant proteases thrombin and Factor 
Xa were inhibited by arginine. Therefore, the concentration of arginine in 
commercial preparations of rtP A appears to have an anticoagulant activity but does 
not retard fibrinolysis. 
INTRODUCTION 
Recombinant tissue plasminogen activator (rtP A) is a serine protease that is 
given systemically by intravenous infusion to treat myocardial infarction and 
pulmonary emboli. Recently we have shown that it is also very effective in lysing 
venous thrombi if the drug is injected directly into the clots [1]. However, for this 
treatment rtPA is administered in a highly concentrated form in a solution that 
contains 35 mg/ml L-arginine (Alteplase, Genentech, Inc., San Francisco, CA). 
Although arginine is necessary to solubilize rtPA at this concentration (1 mg/ml), it 
is also known to inhibit certain proteases [2]. Therefore, there is the possibility that 
the activity of the rtP A that is injected into venous thrombi is significantly inhibited 
by arginine. If this were the case, a lower concentration of rtP A that requires less 
arginine for solubilization and is therefore less inhibited might be just as effective as 
the higher dose we currently use. Reducing the dose of rtP A would result in 
significant cost savings. 
Therefore, we undertook the current work to investigate whether the 
arginine in the rtPA that we use (Alteplase) does in fact inhibit the enzyme's 
activity. 
MATERIALS AND METHODS 
Materials 
Human fibrinogen (Grade L) and human plasmin were obtained from 
American Diagnostica Inc. (Greenwich, CT, USA). Bovine thrombin (100 units/ml) 
-
was obtained from Parke-Davis (Morris Plains, New Jersey, USA). Plasminogen was 
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-purified from human plasma with lysine-Sepharose [3]. Genentech Inc. (San 
Francisco, CA, USA) provided recombinant tissue plasminogen activator (rtP A, 
Alteplase containing 35 mg L-arginine per mg rtPA). The chromogenic substrates 
SPECTROZYME tPA (containing glycine and arginine) and SPECTROZYME PL 
(containing lysine) were acquired from American Diagnostica Inc. A Stachrom 
Heparin kit (with a chromogenic substrate containing leucine, glycine, and arginine) 
from Diagnostica Stago (Asnieres, France) was used in factor Xa analysis. DL-
Arginine, D-Arginine, and L-Arginine were purchased from Sigma (St. Louis, MO, 
USA) and reconstituted with the required buffer to a concentration of 70 mg/ml, 100 
mg/ml, or 150 mg/ml with a pH of 7.4. 
Arginine effect on rtP A and plasmin activity 
One hundred seventy-eight microliters of tris-imidazole buffer (0.22 M NaCI, 
0.029 M tris, 0.029 M Imidazole, pH 8.4) was placed into micro titer wells, followed by 
the addition of 4 JlI rtPA (1 mg/ml stock rtPA with 35 mg/ml L-arginine). After the 
mixtures were warmed to 31lC for 2 minutes, 20 JlI of a chromogenic substrate 
specific for tP A (SPECTROZYME tP A) was added to each well. Color development 
(A4os) was monitored in a kinetic plate reader (Bio-Tek EL 340 Bio Kinetics 
Microplate Reader, Winooski, Vermont, USA) at 31lC for 20 minutes with 
absorbance measurements recorded every 15 seconds. Arginine (either DL, L, or D) 
in tris-imidazole buffer (final added concentration 35 mg/ml) was substituted for the 
tris-imidazole alone. Each concentration was tested in 16 and 12 wells on separate 
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-occasions. Data curves were analyzed to determine the maximum rate of reaction in 
mOD/min (Delta Soft 3.0, Princeton, New Jersey, USA). 
A chromogenic substrate specific for plasmin (SPECTROZYME PL) was 
utilized to determine the effect of arginine on plasmin activity and on the ability of 
rtP A to convert plasminogen to plasmin. In testing plasmin alone, stock solutions 
of 10 IlM plasmin and 5 mM SPECTROZYME PL were warmed to 37lC for 2 minutes 
and then added to microtiter wells to achieve final concentrations of 0.1 IlM 
plasmin and 0.5 mM substrate in 200 III total volume. Some experiments included 
final arginine (DL, L, or D) concentrations of 14 mg/ml or 28 mg/ml. Color 
progression for each concentration was analyzed in 6 wells at 37lC for 7 minutes 
with A 405 measured every 10 seconds. Maximum reaction rates were measured 
from resulting data curves. 
To determine plasminogen activation by rtPA, 80 III of 5 mM plasmin 
substrate (SPECTROZYME PL), 80 III of 3.5 IlM plasminogen, 35 III of Tyrode's buffer 
(140 mM NaCI, 2.67 mM KCI, 1.0 mM MgCl2, 0.47 mM NaH2P04, 2.0 mM CaCl2, 0.94 
mM NaHC03, 5.6 mM glucose, and pH 7.4) with or without 350 mg/ml arginine 
(either DL, L, or D with pH 7.4), and 5 III rtPA (1 mg/ml) were combined in 
microtiter wells after pre-warming to 37lC for 2 minutes. Color development was 
monitored in a kinetic plate reader at 37lC for 8 minutes with absorbances (A 405 
nm) recorded every 10 seconds. Arginine concentrations (0.9 mg/ml derived from 
the rtPA stock alone and 62 mg/ml derived by the addition of arginine stock) were 
tested twice in 2 wells. Maximum rates of reaction were determined from resulting 
data curves. 
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The effect of arginine on plasminogen activation in the presence of fibrin was 
studied with fibrin clots that covered the entire bottom of micro titer wells. These 
were prepared with a 60 JlI mixture of fibrinogen (final concentration 2.4 mg/ml), 
plasminogen (final concentration 0.48 JlM), and bovine thrombin (final 
concentration 33 units/ml). The mixtures were set aside for 10 minutes for 
completion of coagulation. Various arginine (DL, L, or D) concentrations ranging 
from 8.75 mg/ml to 35 mg/ml were prepared by adding 500 JlI of rtPA (0.5 mg/ml) 
and varying the volumes of arginine (70 mg/ml stock) and Tyrode's buffer with 1% 
bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) to produce a final rtP A 
concentration of 0.25 mg/ml in a volume of 1 ml. The clots and arginine/rtPA 
solutions were warmed to 3J70C for 2 minutes. After incubation, 100 JlI aliquots of 
each arginine/tPA solution were placed on top of 12 fibrin clots. Lysis was 
monitored in a kinetic plate reader for 20 minutes by measuring turbidity at A.405 
every 15 seconds. All experiments were performed twice. The data curves were 
analyzed for maximum rates (mOD/min) of fibrinolysis. 
In similar experiments, plasminogen-free clots were overlaid with 100 JlI of a 
solution containing 0.6 JlM plasminogen and 0.15 JlM rtPA with or without 35 
mg/ml DL-arginine. All constituents were warmed to 3J70C for 2 minutes. Each 
concentration of arginine was evaluated in 12 wells in a kinetic plate reader for 40 
minutes at 3J70C; A. 405 nm was measured every 30 seconds. All experiments were 
performed twice. The maximum clot lysis rate (mOD/min) for each concentration 
of arginine was measured. 
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Effect of arginine on Factor Xa activity 
Factor Xa activity in the presence of DL-arginine in TBS/BSA was measured 
using a Stachrom Heparin kit. One hundred microliters of 11 nKat Factor Xa (2.25 
nKat final concentration) stock was added to microtiter wells, followed by 100 J.11 of 
various arginine concentrations (0-50 mg/ml stocks) at pH 7.4. Finally 100 J.11 of 
chromogenic substrate was added to each well, and the reactions were monitored at 
room temperature in a EL 312e Bio-Tek kinetic microplate reader for 5 minutes with 
A405 measurements recorded every 15 seconds. Each concentration was tested twice 
in 3 wells. Resulting data curves were analyzed for maximum reaction rates 
(mOD/min). 
Effect of arginine on thrombin activity 
The effect of arginine on thrombin clotting activity was measured with 
fibrometers (Becton Dickinson Diagnostic Instrument Systems, Sparks, Maryland, 
USA). Ninety microliters of arginine (DL, L, or D) in Tyrode's buffer (pH 7.4; final 
arginine concentrations 0-21 mg/ml) was added to 200 J.11 of fibrinogen (final 
concentration 2.4 mg/ml) in fibrometer cups and warmed to 3~C for one minute. 
Ten microliters of bovine thrombin (5 units/ml) was then immediately injected 
directly into the fibrinogen-arginine mixture. Each concentration of arginine was 
tested 10 times. Because the ionic strength of the reaction mixture was affected by 
the arginine concentration, a control (0.5 M NaCI in 10 mM tris pH 7.5) was included 
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-that had conductivity equal to that of 35 mg/ml arginine in Tyrode's buffer (25 
mmho). 
Effect of arginine on whole blood clotting 
The effect of arginine on whole blood coagulation time was measured in glass 
tubes containing various arginine (DL, L, or D) concentrations (0-35 mg/ml of 
plasma). Each assay included three tubes containing: 67 J.lI of tris-buffered saline 
(TBS; 100 mM NaCI, 41 mM tris HCI, 8.8 mM tris base, and pH 7.35), another 67 J.lI 
0.5 M NaCI in 10 mM tris (pH 7.5), and a final one of 67 J.l1350 mg/ml arginine. To 
each tube was added 933 J.lI of freshly drawn whole blood from one of five normal 
donors. Each tube was immediately mixed briefly at room temperature. Then every 
30 seconds the tubes were gently rocked once. When coagulation became visible, the 
time was noted. 
Statistical Analysis 
Reaction rates with and without the addition of 35 mg/ml DL-arginine were 
compared statistically using the Mann-Whitney U-test for unpaired data (StatView, 
Abacus Concepts, Berkeley, CA, USA). 
Solubility of rtPA in the presence of arginine 
One ml volumes of 1 mg/ml rtPA were dialyzed against solutions of L-
arginine (20 mg/ml, 10 mg/ml, and 5 mg/ml) in TBS for 24 hours at 4°C. Afterward, 
turbidity was measured by optical density readings at A,400" If a precipitate formed, 
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-arginine was added back to attain 35 mg of arginine per mg of rtP A to test rtP A 
resolubility. 
RESULTS 
In all assays, both L-arginine and D-arginine were tested and produced 
indistinguishable results. 
Figure 1 demonstrates the inhibitory effect of various arginine concentrations 
on the reaction between rtP A and its chromogenic substrate (SPECTROZYME tP A). 
As arginine concentration increased to 35 mg/ml, the enzymatic activity of rtPA 
diminished to 36% of the intial rate (Table lola). However, there was no apparent 
effect of 35 mg/ ml arginine on rtP A activation of plasminogen to plasmin when 
either fibrin or a plasmin-specific chromogenic substrate was used (Table 1.1 b, c). 
The lack of effect of 35 mg/ml arginine on plasmin activity was confirmed 
both with a chromogenic substrate (SPECTROZYME PL) and with fibrin clots (Table 
1.2 a, b). 
The effect of arginine on coagulant processes was assessed with three different 
types of experiments. Figure 2 illustrates Factor Xa activity with a chromogenic 
substrate. Increasing the concentration of arginine from 0 mg/ml to 50 mg/ml 
resulted in a 34% decrease in the rate of substrate conversion. 
Assays of thrombin activity with arginine (concentrations 0-21 mg/ml) 
produced similar results (Fig. 3). At 21 mg/ml arginine, the increase in fibrinogen 
clotting time of thrombin was over 4-fold. 
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- In addition, the anticoagulant activity of arginine was tested using whole 
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blood from 5 normal donors. For each donor, the clotting time in the presence of 35 
mg/ml arginine was ~50% longer than the control time (Fig. 4). 
In all coagulation assays a saline control with ionic strength (conductivity) 
equilvalent to the most concentrated arginine solution produced results 
indistinguishable from those obtained in the absence of arginine. 
In studies of rtPA solubility, a precipitate formed as arginine concentration 
was reduced, resulting in increased turbidity (A400, Fig. 5). As arginine was added 
back to achieve 35 mg arginine/mg tPA, the precipitate dissolved (data not shown). 
DISCUSSION 
Our results indicate that the fibrinolytic activity of rtPA is not inhibited by the 
concentration of arginine (35 mg/ml) that is necessary to keep 1 mg/ml of the 
enzyme in solution. Since fibrinolysis is actually dependent upon two enzymatic 
reactions--the conversion of plasminogen to plasmin by tP A and the degradation of 
fibrin by plasmin--we have shown that arginine interferes with neither of these. 
Therefore, injecting the concentrated drug directly into venous thrombi should be 
highly effective, as in fact we have observed it to be [1]. 
On the other hand, arginine does inhibit rtPA activity against a small 
chromogenic substrate that contains arginine (Fig. 1, Table 1). This suggests that in 
its physiologic role rtP A is protected from arginine inhibition by binding to its 
cofactor fibrin and/or by interaction with its substrate plasminogen. Of interest, 
arginine did not inhibit the activity of plasmin against a chromogenic substrate that 
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does not contain arginine (Table 1). Therefore, free arginine presumably competes 
with the arginine moiety in the tP A substrate. 
To pursue potential arginine effects further we tested its activity against two 
coagulation enzymes, Factor Xa and thrombin. Factor Xa activity against an 
arginine-containing chromogenic substrate was inhibited (Fig. 2), similar to the 
effect observed with rtP A. However, arginine also inhibited the ability of thrombin 
to clot fibrinogen (Fig. 3). In this instance, interaction with a large protein substrate 
did not protect the enzyme from arginine inhibition, an observation contrary to the 
case observed for rtP A and plasmin. The inhibitory effect of arginine on coagulation 
was also apparent in a whole blood clotting assay (Fig. 4). In this system, arginine 
could theoretically be interfering with cell-dependent events as well as coagulant 
enzyme activities. 
The effect of arginine on hemostatic mechanisms has apparently not been 
extensively studied previously. We found very little literature on the subject. 
However, using thromboelastography Dambisya and Lee demonstrated that L-
arginine causes hypocoagulability at concentrations (eg. 1.4 J..lg/ml) much lower than 
those we studied; yet fibrinolysis was not affected [4]. In contrast, Udvardy, et al., 
recently reported that micromolar concentrations of arginine enhanced in vitro lysis 
of plasma clots in response to added tPA [5]. Neither of these groups tested the 
much greater concentrations of arginine that we studied. 
It appears, therefore, that our concern that arginine retards the effect of rtP A 
in lysing venous thrombi was unfounded. On the basis of our in vitro studies and 
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the limited amount of information in the literature, we conclude that arginine does 
not inhibit fibrinolysis and in fact apparently has anticoagulant activity. 
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Table 1. Reaction rates (mOD/min) of rtPA and plasmin 
Control 35 mg/ ml arginine P value'" 
median (range) median (range) 
1) tPA tests 
a) tPA chromogenic substrate (n=16) 61 (15) 22 (10) <0.0001 
b) fibrinolysis (n=9) 20 (10) 22 (18) 0.21 
c) plasminogen activation (n=4) 282 (81) 246 (56) 0.25 
(plasmin chromogenic substrate) 
2) plasmin tests 
a) plasmin chromogenic substrate (n=6) 201 (31) 193 (22) 0.26 
b) fibrinolysis (n=21) 5.2 (5.3) 5.4 (6.4) 0.27 
... Determined by Mann-Whitney U-test for unpaired data 
-
-FIGURE LEGENDS 
Figure 1. Arginine inhibition of rtP A activity against its chromogenic substrate 
(SPECTROZYME tPA): a) control, no added arginine; b) 8 mg/ml added arginine; 
c) 22 mg/ml added arginine; d) 35 mg/ml added arginine. In all cases, rtPA 
provided an additional 0.7 mg/ml arginine to the system. 
Figure 2. Effect of arginine on Factor Xa activity against its chromogenic substrate. 
Curves similar to those produced in Fig. 1 were used to determine the maximum 
reaction rates (mOD/min) at each arginine concentration. Data points represent the 
mean reaction rate ± one standard devation (n=3-6). 
Figure 3. Arginine effect on thrombin (5 units/ ml) clotting time of fibrinogen. Each 
point represents the mean coagulation time ± one standard deviation (n=9-13). 
Figure 4. Anticoagulant activity of arginine in whole blood from 5 normal donors. 
Rate of coagulation was visually monitored by gently rocking glass tubes containing 
o or 35 mg/ml arginine per ml of plasma in whole blood. 
Figure 5. Solubility of rtP A in the presence of arginine. The vertical axis represents 
turbidity measurements at A400• 
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